Literature DB >> 21511994

Is there an association between external cardioversions and long-term mortality and morbidity? Insights from the Atrial Fibrillation Follow-up Investigation of Rhythm Management study.

Claude S Elayi1, Matthew G Whitbeck, Richard Charnigo, Jignesh Shah, Tracy E Macaulay, Gustavo Morales, John C Gurley, Bahram Kakavand, Sergio Thal, Chi Keong Ching, Yaariv Khaykin, Atul Verma, Conor Barrett, Rong Bai, Luigi Di Biase, Abhijit Patwardhan, David J Moliterno, Andrea Natale.   

Abstract

BACKGROUND: Cardiac electric therapies effectively terminate tachyarrhythmias. Recent data suggest a possible increase in long-term mortality associated with implantable cardioverter-defibrillator shocks. Little is known about the association between external cardioversion episodes (ECVe) and long-term mortality. We sought to assess the safety of repeated ECVe with regard to cardiovascular mortality and morbidity. METHODS AND
RESULTS: We analyzed the data of the 4060 patients from the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial. In particular, associations of ECVe with all-cause mortality, cardiovascular mortality, and hospitalizations after ECVe were studied. Over an average follow-up of 3.5 years, 660 (16.3%) patients died, 331 (8.2%) from cardiovascular causes. A total of 207 (5.1%) and 1697 (41.8%) patients had low ejection fraction and nonparoxysmal atrial fibrillation, respectively; 2460 patients received no ECVe, whereas 1600 experienced ≥ 1 ECVe. Death occurred in 412 (16.7%), 196 (16.5%), 39 (13.5%), and 13 (10.4%) of patients with 0, 1, 2, and ≥ 3 ECVe, respectively. There was no significant association between ECVe and mortality within any of the 4 subgroups defined by ejection fraction and atrial fibrillation type, although myocardial infarction, coronary artery bypass graft, and digoxin were significantly associated with death (estimated hazard ratios, 1.65, 1.59, and 1.62, respectively; P < 0.0001). ECVe were associated with increased cardiac hospitalization reported at the next follow-up visit (39.3% versus 5.8%; estimated odds ratio, 1.39; P < 0.0001).
CONCLUSIONS: In the AFFIRM study, there was no significant association between ECVe and long-term mortality, even though ECVe were associated with increased hospitalizations from cardiac causes. Digoxin, myocardial infarction, and coronary artery bypass graft were significantly associated with mortality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21511994     DOI: 10.1161/CIRCEP.110.960591

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  2 in total

1.  Acute Effects of Implantable Cardioverter-Defibrillator Shocks on Biomarkers of Myocardial Injury, Apoptosis, Heart Failure, and Systemic Inflammation.

Authors:  Jordan Brewster; Travis Sexton; Gary Dhaliwal; Richard Charnigo; Gustavo Morales; Kevin Parrott; Yousef Darrat; John Gurley; Susan Smyth; Claude S Elayi
Journal:  Pacing Clin Electrophysiol       Date:  2017-03-08       Impact factor: 1.976

2.  Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction.

Authors:  Sebastiano Virgadamo; Richard Charnigo; Yousef Darrat; Gustavo Morales; Claude S Elayi
Journal:  World J Cardiol       Date:  2015-11-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.